丹麦DERMBIO登记:乌司奴单抗与司库奇尤单抗治疗中重度斑块状银屑病患者的特征比较
基于丹麦全国DERMBIO登记,比较首次接受乌司奴单抗(1037例)与司库奇尤单抗(142例)治疗的中重度斑块状银屑病患者特征。结果显示司库奇尤单抗组年龄更大、病程更长、关节病患病率更高(44.4% vs 22.7%),乌司奴单抗组生物制剂初治比例更高(52.9% vs 14.5%),PASI显著更高(10.4 vs 7.3,P<0.0001)。
要点
- 乌司奴单抗组生物制剂初治比例52.9%,司库奇尤单抗组仅14.5%。
- 司库奇尤单抗组关节病患病率44.4%,显著高于乌司奴单抗组的22.7%。
- 乌司奴单抗组PASI均值10.4,显著高于司库奇尤单抗组的7.3(P<0.0001)。
核心结论
- 真实世界中,首次接受乌司奴单抗与司库奇尤单抗治疗的患者特征存在显著差异。
研究设计与样本
- 基于丹麦全国DERMBIO登记,比较首次接受乌司奴单抗(1037例)与司库奇尤单抗(142例)治疗的中重度斑块状银屑病患者特征。
主要发现
- 乌司奴单抗组生物制剂初治比例52.9%,司库奇尤单抗组14.5%。
- 司库奇尤单抗组关节病患病率44.4%,乌司奴单抗组22.7%。
- 乌司奴单抗组PASI均值10.4,显著高于司库奇尤单抗组的7.3(P<0.0001)。
- DLQI均值乌司奴单抗组11.6,司库奇尤单抗组10.0(P=0.0769)。
- 两组均以男性为主,司库奇尤单抗组年龄稍大、病程更长。
临床怎么用
- 解读银屑病生物制剂临床试验与登记数据时,需考虑真实世界中患者特征差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: While safety and efficacy of ustekinumab and secukinumab, monoclonal antibodies approved for psoriasis, are described in clinical trials, data on their real-life application are lacking. OBJECTIVE: We compared the characteristics of patients initiating first-time treatment with secukinumab or ustekinumab. METHODS: All Danish patients with moderate-to-severe plaque psoriasis treated with biologics are recorded in the nationwide DERMBIO registry. We compared characteristics of patients starting first-time therapy with ustekinumab and secukinumab, respectively. RESULTS: We identified a total of 1037 and 142 first-time treatment series with ustekinumab and secukinumab. There was a male predominance in both groups, but patients initiating secukinumab were slightly older and with longer disease duration; in agreement with guidelines for biologic treatment in Denmark where ustekinumab has been first line for all with psoriasis without joint problems since 2012, and secukinumab first line for psoriasis with joint problems since July 2016. A total of (52.9% and 14.5%) patients receiving ustekinumab and secukinumab, respectively, were bio-naïve. The mean dermatology life quality index score was slightly higher for ustekinumab than secukinumab (11.6 vs. 10.0; P = 0.0769); the mean Psoriasis Area and Severity Index score were significantly higher (10.4 vs. 7.3; P < 0.0001) for ustekinumab. Prevalence of joint disease was markedly lover (22.7% vs. 44.4%) among patients receiving ustekinumab. CONCLUSIONS: We found significant differences in characteristics of patients starting therapy with ustekinumab and secukinumab in a real-life clinical setting. These findings may aid clinicians and researchers when interpreting efficacy data derived from clinical trials and biologic registries of patients with psoriasis.
引用
- Egeberg A, Iversen L, Gniadecki R, et al. Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis - nationwide results from the DERMBIO registry. J Eur Acad Dermatol Venereol. 2017. PMID: 28273375. doi:10.1111/jdv.14200
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。